1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Fluicell AB

Fluicell AB

26.50
SEK
-0.60
(-2.21%)
2.04EPS
14.82P/E
41.49MMarket Cap
Nov 13Next Earn
Fluicell AB
STO:FLUI
(Nasdaq Stockholm)

Recent

price

26.50

P/E

ratio

14.82

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
31.6
12.61
11.93
24.22
28.16
15.81
10.8
9.98
1.35
4.37
13.42
Revenue per Share
- -
-59.35
-89.57
-143.08
-181.39
-106.87
-131.8
-71.8
-79.41
-11.29
-6.07
2.04
Basic EPS, GAAP
- -
-66.91
-99.89
-136.46
-174.05
-108.76
-117.94
-73.7
-81.42
-11.41
-3.6
-0.12
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
8.32
22.07
114.89
227.5
99.53
118.46
116.11
77.92
1.27
14
7.94
11.99
Book Value per Share
8.32
22.07
108.95
223.16
95.67
116.36
114.32
77.1
0.68
11.35
0.34
2.66
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Basic Weighted Avg Shares
- -
3
1
1
2
5
3
3
3
2
6
18
Sales/Revenue/Turnover
- -
-188.46
-706.84
-1,205.38
-750.92
-367.34
-833.78
-668.29
-805.24
-852.18
-139.87
14.12
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
- -
- -
- -
Depreciation Expense
- -
-5
-7
-15
-19
-18
-22
-22
-27
-16
-8
3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-187.86
-710.08
-1,199.02
-749
-379.5
-833.7
-664.6
-795.51
-834.37
-138.82
15.18
Profit Margin (%)
1
2
9
21
2
18
17
21
-1
15
- -
3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
2
10
23
10
19
19
23
- -
19
11
16
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.38
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.32
Return on Capital (%)
- -
-390.53
-130.79
-89.21
-110.93
-118.36
-112.37
-101.54
-222.48
-157.8
-55.3
18.57
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
14
15
41

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8
9
12
Cash, Cash Equivalents & STI
2
1
- -
Accounts Receivable, Net
1
3
8
Inventories
3
3
3
Total Current Liabilities
8
7
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
506.9%
860.97%
-43.32%
Free Cash Flow
- -
-13.09%
-68.45%
Net Income, GAAP
- -
-8.41%
-46.28%
Sales/Revenue/Turnover
- -
32.46%
222.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
1
1
2
2025
- -
1
1
4
6
2026
6
7
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-8.61
-4.79
-0.77
-1.04
-11.29
2025
-2.92
-2.1
-2.09
0.07
-6.07
2026
2.41
1.65
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Fluicell AB (publ) operates as a life science company focused on high-precision bioprinting, single-cell biology solutions, and tissue engineering platforms for regenerative medicine and drug development. The company offers core research instruments including BIOPEN, a microfluidic platform for high-precision single-cell solution delivery and microenvironment control; Biozone 6 for generating dose-response curves and studying multiple drug compounds; Dynaflow Resolve, an ion channel screening platform for patch-clamp recordings; Biopixlar, a 3D single-cell bioprinting system enabling high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform suited for fume hoods or biosafety cabinets; alongside accessory and consumable products for bioprinting and single-cell applications. Its Nexocyte platform drives universal tissue production, supporting transplantable tissues for conditions such as type 1 diabetes, cardiac toxicity screening, kidney disease models, and other metabolic, pulmonary, and cardiovascular diseases, with a primary pipeline emphasis on engineered pancreatic islets for type 1 diabetes therapeutics featuring immune protection, controlled composition, and dual insulin-glucagon secretion. Fluicell AB (publ) serves pharmaceutical companies, medical research institutions, and scientists worldwide, primarily targeting drug screening, regenerative medicine, and therapeutic development in oncology, cardiology, nephrology, and endocrinology. The company maintains global operations with a focus on Europe and North America partnerships. Founded in 2012 as a spin-off from Chalmers University of Technology and headquartered in Biotech-Huset, Arvid Wallgrens Backe 20, Gothenburg (Mölndal area), Sweden, it trades on the Spotlight Stock Market under ticker FLUI.ST. In recent developments, Fluicell entered an exclusive global license and development agreement with Ambusol AB in September 2025 for cancer treatment technology, incorporating the Nexocyte microflow platform and a new catheter adaptation, potentially yielding up to SEK 142 million in upfront, license, and milestone payments across five cancer indications plus royalties. In August 2025, the company secured funding from Breakthrough T1D to collaborate with a leading medical university on tissue-based type 1 diabetes therapeutics. Additional advancements include November 2025 research on a bioengineering toolbox for cancer interception and September 2025 publication of a new single-cell spatial transcriptomic profiling method for engineered tissues.